Sangamo is pioneering the future of genomic medicine
Sangamo Therapeutics is a genomic medicine company dedicated to translating groundbreaking science into medicines that transform the lives of patients and families afflicted with serious neurological disease. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today’s medicine can only offer symptom management at best.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
-
May 9, 2024
Showcased 20 presentations at the 27 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel delivery capsid, STAC-BBB, that demonstrated industry-leading blood-brain barrier (BBB)
-
May 9, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--May 9, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
-
May 2, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--May 2, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024 .
-
April 22, 2024
RICHMOND, Calif. --(BUSINESS WIRE)--Apr. 22, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27 th ASGCT Annual Meeting being held May
| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
-
May 14, 2024 from 8:30 AM to 8:55 AM EDT
-
May 9, 2024 at 4:30 PM EDT